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Abstract
Well-developed point-of-care (POC) cancer screening tools have the potential to provide
better cancer care to patients in both developed and developing countries. However, new
medical technology will not be adopted by medical providers unless it addresses a popula-
tion’s existing needs and end-users’ preferences. The goals of our study were to assess pri-
mary care providers’ level of awareness, interest, and preferences in using POC cancer
screening technology in their practice and to provide guidelines to biomedical engineers for
future POC technology development. A total of 350 primary care providers completed a
one-time self-administered online survey, which took approximately 10 minutes to com-
plete. A $50 Amazon gift card was given as an honorarium for the first 100 respondents to
encourage participation. The description of POC cancer screening technology was pro-
vided in the beginning of the survey to ensure all participants had a basic understanding of
what constitutes POC technology. More than half of the participants (57%) stated that they
heard of the term “POC technology” for the first time when they took the survey. However,
almost all of the participants (97%) stated they were either “very interested” (68%) or “some-
what interested” (29%) in using POC cancer screening technology in their practice. Demo-
graphic characteristics such as the length of being in the practice of medicine, the
percentage of patients on Medicaid, and the average number of patients per day were not
shown to be associated with the level of interest in using POC. These data show that there
is a great interest in POC cancer screening technology utilization among this population of
primary care providers and vast room for future investigations to further understand the
interest and preferences in using POC cancer technology in practice. Ensuring that the ben-
efits of new technology outweigh the costs will maximize the likelihood it will be used by
medical providers and patients.
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Introduction
Point-of-care (POC) testing is defined as “testing at or near the site of patient care whenever
the medical care is needed”. POC testing can play an important role in cancer care, which is a
continuous process from prevention, screening, diagnosis, treatment to survivorship. Appro-
priate and timely treatment decisions can be made when physicians are given immediate infor-
mation about patients’ condition by using POC testing, which will lead to reduced patients’
morbidity, mortality, criticality, and therefore increase the chances of survival [1,2]. As the can-
cer care continuum includes multiple technical stages, communication steps, and interactions
between patients, providers, and organizations, using POC testing can help reduce the number
of steps in each process and help ensure more patients stay within the system to receive the
care they need [3,4].
POC testing has the potential to resolve issues such as inconvenient scheduling times, long
waits, and variability in healthcare services that are reported barriers in accessing follow-up
care for cancer [2]. The goal of POC testing is to produce rapid results without the need for
repeated visits to facilitate the timely implementation of appropriate treatment [5,6]. POC
technology may be able to reduce the number of steps in the care continuum by bringing the
test closer to the patient care site, and by removing reported barriers, as well as shortening the
turnaround time and facilitating clinical management decisions [3,7].
The existing examples of POC technology demonstrate its potential for better disease moni-
toring and control for infectious disease, diabetes, and cancer in low- and high-resource set-
tings [8]. Various novel POC cancer screening tools are now available for use in practices
around the world. For example, Digital Breast Tomosynthesis, which is a new way of screening
for breast cancer using 3-D mammograms, is being rapidly implemented in breast imaging
clinics around the world [9]. A pilot-study to measure sensitivity of a mobile POC system for
measuring breast cancer biomarkers for breast cancer screening has been shown to predict
women with breast cancer and abnormal mammograms, which suggests the potential to reduce
unnecessary mammograms without losing diagnostic sensitivity [10].
Located at Boston University School and funded by National Institute of Biomedical Imag-
ing and Bioengineering, the Center for Future Technology in Cancer Care (CFTCC) is seeking
to improve the quality of cancer care through the identification and prototyping of innovative
point of care technologies. Conducting user research and the integration of the results into
product development are well-recognized important factors in medical device development
[11]. In order to ensure that newly developed cancer screening POC technologies meet existing
needs and expectations of medical providers, CFTCC surveyed primary care providers includ-
ing primary care physicians, family physicians, and advanced practice nurses to assess their
level of awareness, interest, and preferences in using POC cancer screening technology in their
practice and to provide guidelines to biomedical engineers for future POC technology
development.
Methods
Study Population/Recruitment
The survey was distributed through the following three outlets– 1) the link to the online survey
was forwarded to primary care providers by Boston Medical Center and two of its affiliated
community health centers, and also by the Department of Public Health LA County, 2) the
link to the survey was forwarded to the members in the Center for Integration of Medicine and
Innovative Technology (CIMIT) listserv, 3) it was posted on the CFTCC website (http://www.
bu.edu/cftcc/category/cftcc-survey/). The recruitment letter stated that the survey was only for
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primary care providers including primary care physicians, family physicians, and nurse practi-
tioners. To encourage people to participate, a $50 Amazon Gift Card was provided as an hono-
rarium for the first 100 respondents. This study was exempted by Institutional Review Board
(IRB) of Boston University. The survey was distributed throughout the second and third week
of January 2014 and deactivated on February 24, 2014.
Survey Instrument
We developed a 27-item survey, which used a Likert response, multiple choice and write-in
responses. Participants were asked to rate their agreement with statements such as “it is my
first time hearing the term point-of-care technology”, “I know what point-of-care cancer
screening technology is”, and “I understand why point-of-care cancer screening technology
could be useful”. Two questions were asked to rank potential advantages and important fea-
tures of POC cancer screening technology, and two questions to rank provider- and system-
level barriers to providing cancer prevention care.
The level of interest in using POC cancer screening technology was assessed by asking the
participants to choose one of the four options–“not interested at all”, “not very interested”,
“somewhat interested”, and “very interested”. The outcome of interest was dichotomized with
“very interested” as one group, and the “somewhat interested”, “not very interested” and “not
interested at all” as one group.
Based on the general description of POC technology, we defined “POC cancer screening
technology” as “a cancer screening test occurring at the point where patient care is given, wher-
ever that is located; for example, patient’s bedside, pharmacy, physician’s office, or patient’s
home, instead of having to be referred to a different location and/or at a different time” [1,12].
The definition of POC was provided at the very beginning of the survey to ensure all partici-
pants had a basic understanding of what constitutes POC technology.
Data Analysis
Data were described with frequencies and percentages in order to measure clinicians’ aware-
ness, interest, and preferences in using POC. Chi-square analyses were used to test associations
between various independent variables and the outcome variable “interest of using POC cancer
screening technology” and “understanding why POC could be useful”. Multivariate logistic
regression analysis was used to analyze the effect of multiple demographic variables on various
outcomes of interest. Odds ratios, 95% confidence intervals, and p-values were reported for
each association, and p-values less than 0.05 were considered to be significant. Data were ana-
lyzed using SAS 9.3.
Results
Respondent Characteristics
Overall, 415 subjects began the online survey. Sixty-five participants (16%) were excluded from
the analysis because they either did not complete the survey and/or were not a primary care
provider. Three hundred fifty people were included in the final analyses. Demographic charac-
teristics of 350 participants are presented in Table 1. Over 40% of the respondents were from a
non-academic hospital, while 33% and 25% of the respondents were from an academic hospital
and community health center, respectively. Most of the participants (97%) reported to have at
least 25% of their patients on Medicaid. Seventy five percent of participants stated that they
spent more than 5 minutes discussing cancer screening recommendations with their patients.
Point-of-Care Cancer Screening Technology
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Awareness and Interest in Using POC Cancer Screening Technology
Three survey questions were asked to assess primary care providers’ awareness of POC cancer
screening technology. More than half of the participants (57%) stated that they heard of the
term “POC technology” for the first time when they took the survey (Table 2). However, after
reading the provided definition of POC cancer screening technology, 89% of the respondents
reported to understand the purpose and usefulness of POC technology. Participants were
asked to choose their interest level of using POC cancer screening technology in their practice.
Table 1. Demographic Characteristics of Study Participants.
Characteristics Primary Care Physician (%)
(n = 269)
Advanced Nurse Practitioner (%)
(n = 81)
All Respondents (%)
(N = 350)
Gender
Male 170 (63.20) 26 (32.10) 196 (56.00)
Female 99 (36.80) 55 (67.90) 154 (44.00)
Organization
Academic Hospital 98 (36.43) 19 (23.46) 117 (33.43)
Non-Academic 110 (40.89) 32 (39.51) 142 (40.57)
CHC 60 (22.30) 29 (35.80) 89 (25.43)
Other 1 (0.37) 1 (1.23) 2 (0.57)
Years in Practice
0–5 yrs 47 (17.47) 10 (12.35) 57 (16.29)
6–15 yrs 108 (40.15) 35 (43.21) 143 (40.86)
16–25 yrs 83 (30.86) 27 (33.33) 110 (31.43)
26–35 yrs 29 (10.78) 7 (8.64) 36 (10.29)
Over 36 yrs 2 (0.74) 2 (2.47) 4 (1.14)
Patients on Medicaid
Less than 25% 8 (2.99) 1 (1.23) 9 (2.58)
25%-50% 79 (29.48) 25 (30.86) 104 (29.80)
51%-75% 141 (52.61) 42 (51.85) 183 (52.44)
More than 75% 39 (14.55) 12 (14.81) 51 (14.61)
I don’t know 1 (0.37) 1 (1.23) 2 (0.57)
Number of Patients per Day
0–10 patients 15 (5.58) 8 (9.88) 23 (6.57)
11–20 patients 94 (34.94) 21 (25.93) 115 (32.86)
21–30 patients 106 (39.41) 35 (43.21) 141 (40.29)
31–40 patients 36 (13.38) 13 (16.05) 49 (14.00)
More than 40 18 (6.69) 4 (4.94) 22 (6.29)
Time Spent per Patient
Less than 10 mins 3 (1.12) 2 (2.47) 5 (1.43)
11–20 mins 105 (39.03) 26 (32.10) 131 (37.43)
21–30 mins 118 (43.87) 40 (49.38) 158 (45.14)
More than 30 mins 43 (15.99) 13 (16.05) 56 (16.00)
Time Spent for Cancer
Discussion
0 min 2 (0.74) 0 (0) 2 (0.57)
1–5 mins 79 (29.37) 9 (11.11) 88 (25.14)
5–10 mins 145 (53.90) 46 (56.79) 191 (54.57)
More than 10 mins 43 (15.99) 26 (32.10) 69 (19.71)
doi:10.1371/journal.pone.0145215.t001
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Over two-thirds of participants (68%) expressed that they were “very interested” in using POC
cancer screening tests in their practice, while 29% said they were “somewhat interested”, and
only 2% stated they were “not very interested”. Among those participants who expressed their
interest in using POC screening test, 43% of them chose “no need to refer” and another 43%
chose “better cancer prevention care will be provided” as their primary reasons for being inter-
ested in POC technology.
Table 2. Knowledge of and Interest in Using POC Technology.
Variables All
Respondents
This is my first time hearing POC
Strongly Agree 113 (32.29)
Agree 86 (24.57)
Disagree 67 (19.14)
Strongly Disagree 84 (24.00)
I know what POC is
Strongly Agree 168 (48.00)
Agree 145 (41.43)
Disagree 29 (8.29)
Strongly Disagree 8 (2.29)
I understand why POC could be useful
Strongly Agree 186 (53.30)
Agree 126 (36.10)
Disagree 33 (9.46)
Strongly Disagree 4 (1.15)
How interested would you be in using a new point-of-care cancer screening technology
in your practice if it were available?
Very Interested 234 (68.22)
Somewhat Interested 100 (29.15)
Not Very Interested 7 (2.04)
Not Interested At All 2 (0.58)
Primary reason for being interested in using a cancer screening point-of-care
technology
No need to refer 145 (43.41)
Not satisfied with current methods 44 (13.17)
Better cancer prevention care will be provided 145 (43.41)
Ideal way to communicate the test results when result is positive
In person 145 (42.27)
On the phone 75 (21.87)
Via email 93 (27.11)
Interactive smartphone app 30 (8.75)
Ideal way to communicate the test results when result is negative
In person 133 (38.78)
On the phone 84 (24.49)
Via email 85 (24.78)
Interactive smartphone app 41 (11.95)
doi:10.1371/journal.pone.0145215.t002
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Interest in Using Interactive Smartphone Applications for
Communicating Test Results
For both positive and negative cancer screening test results, respondents preferred in-person
communication (42% and 39%, respectively) over phone, email, or smartphone application
(Table 2). Using an “interactive smartphone app” to communicate positive and negative
screening test results was least preferred by study participants (9% and 12%, respectively).
Needs and Barriers to Providing Cancer Care
Having to discuss competing health risks with their patients (35%) was shown to be the most
significant provider-level barrier in providing cancer care, followed by lack of support staff
(21%) and lack of result feedback (18%) (Table 3). Difficulty scheduling for a screening test
(32%) was the most significant system-level barrier followed by multiple steps/days for screen-
ing test (24%) and lack of efficient follow-up/monitoring system (23%). Colorectal cancer
(41%) was chosen to be the cancer type that clinicians reported having the greatest need for
improvement with the help of POC technology followed by breast cancer (34%) and prostate
cancer (24%). The most significant advantages of new POC technology included rapid data
Table 3. Needs and Barriers to Providing Cancer Care.
Measure All Respondents
Most important potential advantage of POC technology
Rapid data availability 108 (31.49)
User-friendly 99 (28.86)
Potential cost-savings 81 (23.62)
Making screening a one-time visit 33 (9.62)
Removing intermediary 22 (6.41)
Most important feature of POC technology
Finding cancer in its early stage 124 (36.58)
Distinguishing aggressive vs. benign cancer 101 (29.79)
Requiring a short amount of time for screening 56 (16.52)
Not interrupting current workflow 39 (11.50)
Easy interpretation of the results 19 (5.60)
Most significant provider-level barrier
Having to discuss competing health risks 118 (34.71)
Lack of support staff 72 (21.18)
Lack of screening reminders 52 (15.29)
Lack of result feedback 61 (17.94)
Lack of knowledge on current recommendations 37 (10.88)
Most significant system-level barrier
Difficulty scheduling for screening test 111 (32.46)
Multiple steps/days for screening test 83 (24.27)
Lack of efficient follow-up/monitoring system 79 (23.10)
Lack of social protection for medical leave for patients 42 (12.28)
Lack of cancer prevention education material 27 (7.89)
Which cancer type has most room for improvement
Breast 117 (34.41)
Colorectal 140 (41.18)
Prostate 83 (24.41)
doi:10.1371/journal.pone.0145215.t003
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availability (31%), user-friendly (29%), and potential cost-savings (24%), while the most
important features included finding cancer in its early stage (37%) and distinguishing aggres-
sive from benign cancer (30%).
Factors Impacting the Level of Interest in Using POC technology
A bivariate analysis showed respondents who were exposed to the term POC for the first time
when taking the survey had 1.64 times the odds [95% CI (1.04–2.60), p-value = 0.04] of being
“very interested” in using POC cancer screening technology when compared to those who had
previously heard of the term. Participants with basic understanding of POC had 1.96 times the
odds [95% CI (0.96–3.97), p-value = 0.06] of being strongly interested in using POC compared
to those participants without basic understanding. In addition, participants who said they
understood the usefulness of POC had 5.25 times the odds [95% CI (2.51–10.96), p-value
<0.0001] of being strongly interested in using POC compared to those who said they did not
know its usefulness (Table 4). However, a multivariate analysis including all significant bivari-
ate findings found only “understanding” to still be a significant predictor of interest with those
who understood why POC could be useful having 5.05 times the odds [95% CI (2.36–10.83), p-
value<0.0001] of being “very interested” in using POC cancer screening technology (Table 5).
The length of practicing medicine, the percentage of Medicaid patients, the average number
of patients per day, and the time spent with a patient per annual visit were not shown to be
associated with the level of interest in using POC. In the bivariate analysis, clinicians who
spend between five to ten minutes discussing cancer-related issues with their patients were
more likely to be “very interested” in using POC in their practice compared to those who spend
less than or equal to five minutes [p-value = 0.03]. In the multivariate model, the 5–10 minute
group appeared to be a significant predictor of interest [p-value = 0.03], however this group
was not statistically different in interest level [OR = 1.70, 95% CI (0.97–2.98)] when compared
to those who spend less than 5 minutes or more than 10 minutes discussing cancer screening
recommendations (Table 5). Gender, current position, and organization type were not shown
to be associated with the level of clinicians’ interest in using POC.
Factors Impacting Understanding Why POC Could be Useful
A bivariate analysis of factors impacting understanding of why POC could be useful showed
respondents who expressed they knew what POC was had 35.66 times the odds [95% CI
(14.93–85.15), p-value<0.0001] of understanding why POC could be useful. Additionally,
those who were exposed to the term POC for the first time when taking the survey had 2.70
times the odds [95% CI (1.32–5.53), p-value = 0.007] of understanding why POC could be use-
ful when compared to those who had heard the term before. Advanced nurse practitioners had
0.33 times the odds [95% CI (0.16–0.67), p-value = 0.002] of understanding why POC could be
useful when compared to primary care physicians (Table 6). However, in the multivariate logis-
tic regression analysis of these variables only position appeared to be a significant predictor of
understanding why POC could be useful. Advanced Nurse Practitioners had 0.34 times the
odds [95% CI (0.15–0.71), p-value = 0.005] of understanding why POC could be useful when
compared to Primary Care Physicians indicating physicians were more likely to understand
why POC could be useful (Table 7).
Percentage of patient population on Medicaid, number of patients seen per day, time spent
with a patient during annual check-up, time spent discussing cancer screening recommenda-
tions, gender, and organization type were not shown to be associated with understanding why
POC could be useful (Table 6). In the bivariate model, length of time spent practicing medicine
was shown to be a significant predictor of understanding why POC could be useful for those
Point-of-Care Cancer Screening Technology
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Table 4. Bivariate Analysis of Interest Level in Using POC.
Variables N
(Percent)
OR 95% CI P-Value
First time hearing the term POC
Yes 199 (58.85) 1.6409 1.0375–2.5953 0.0355
No 145 (41.15)
I know what POC is
Yes 309 (89.83) 1.9559 0.9634–3.9705 0.0598
No 35 (10.17)
I understand why POC could be useful
Yes 308 (89.53) 5.2471 2.5119–
10.9603
<.0001
No 36 (10.47)
How long have you been in the practice of medicine?
0–5 years (reference) 56 (16.28) 1 - -
6–15 years 142 (41.28) 1.004 0.512–1.967 0.9917
16–25 years 107 (31.10) 0.825 0.412–1.653 0.5867
26 years or more 39 (11.34) 0.981 0.404–2.381 0.9658
What percentage of your patient population is on Medicaid?
< = 50% (reference) 109 (31.78) 1 - -
51%-75% 183 (53.35) 0.843 0.508–1.399 0.5084
> = 75% 51 (14.87) 1.648 0.755–3.599 0.2095
How many patients do you see per day?
0–10 patients 22 (6.40) 1 - -
11–20 patients 110 (31.98) 0.656 0.238–1.812 0.4162
21–30 patients 141 (40.99) 0.827 0.303–2.255 0.7102
31–40 patients 49 (14.24) 1.462 0.4553–4.700 0.5233
More than 40 patients 22 (6.40) 0.542 0.153–1.921 0.3425
How much time do you spend with a patient per visit during an annual check-up?
< = 20 minutes (reference) 134 (38.95) 1 - -
21–30 minutes 156 (45.35) 1.059 0.642–1.746 0.823
> = 30 minutes 54 (15.70) 0.776 0.400–1.505 0.4529
How much time do you or members of your team spend discussing cancer screening
recommendations?
< = 5 minutes (reference) 86 (25.00) 1 - -
5–10 minutes 189 (54.94) 1.808 1.058–3.090 0.0302
> = 10 minutes 69 (20.06) 1.466 0.754–2.849 0.2589
Gender
Male 192 (55.81) 0.6901 0.4372–1.0894 0.1294
Female 152 (44.19)
Position
Primary care physician 264 (76.74) 1.108 0.6435–1.9079 0.7844
Advanced nurse practitioner 80 (23.26)
Organization type
Academic medical center (reference) 115 (33.43) 1 - -
Hospital–non-academic 142 (41.28) 0.99 0.585–1.675 0.97
Community health center 87 (25.29) 1.113 0.609–2.034 0.7281
doi:10.1371/journal.pone.0145215.t004
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practicing 16 years or more [p-value = 0.04]. However, this group did not demonstrate a higher
likelihood of understanding why POC could be useful when compared to those who practiced
medicine for less than 16 years [OR = 0.23, 95% CI (0.05–1.03)] and was not significant in the
multivariate analysis (Tables 6 and 7).
Discussion
The potential benefits of POC cancer screening technology are clear both nationally and glob-
ally [8,13]. As the result of a rapidly growing interest of POC technology, biomedical engineers
may become easily attracted to developing new technologies before carefully considering pref-
erences and needs of clinicians. Our study findings may help medical communities, as well as
POC cancer screening technology developers, to have better understandings of how POC can-
cer testing is perceived by medical providers before committing their resources on adopting or
developing such technologies.
There seems to be a lack of exposure to the concept of POC technology among our partici-
pants as a majority (57%) of participants heard the term POC cancer screening technology for
the first time when they took this survey. However, the vast majority of the participants (97%)
expressed interest in using POC technology after being given the description of POC and how
it could potentially be useful in their practice. This data suggests the potential for well-devel-
oped POC cancer screening technology to be accepted and adopted in primary care settings if
designed to overcome some of the existing barriers to providing cancer care including cost,
legality, time, fear, usefulness, and complexity [5].
The lack of clinicians’ interest in using mobile applications in communicating with their
patients was shown in our result. Some mobile phone-based applications have shown to improve
health outcomes for various health conditions, which sparked engineers to pursue the develop-
ment of newmobile medical applications [14]. Mobile applications can be used for various pur-
poses by medical providers such as the direct provision of care, real-time monitoring of patient
vital signs, delivery of patient information to practitioners, and collection of data [15]. Using
mobile applications can also help patients become more committed to the healthy and cancer-
preventive lifestyle, which is a very significant factor in cancer development [16]. With the devel-
opment of advanced cell-phone technologies, tailoring information in real time according to
individuals’ needs has become possible [17]. However, our results suggest that primary care pro-
viders prefer in-person communication over technology-dependent communication methods for
Table 5. Multivariate Analysis of Interest Level in Using POC.
Variables N
(Percent)
OR 95% CI P-Value
First time hearing the term POC
Yes 199 (58.85) 1.513 0.928–2.468 0.0969
No 145 (41.15)
I understand why POC could be useful
Yes 308 (89.53) 5.051 2.357–
10.825
<.0001
No 36 (10.47)
How much time do you or members of your team spend discussing cancer screening
recommendations?
< = 5 minutes (reference) 86 (25.00) 1 - -
5–10 minutes 189 (54.94) 1.698 0.966–2.984 0.0316
> = 10 minutes 69 (20.06) 0.999 0.496–2.012 0.3869
doi:10.1371/journal.pone.0145215.t005
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conveying positive and negative test results. This preference is easily understandable for commu-
nicating positive results as physicians will need to further explain the test results and next steps
with the patients. It will be interesting for researchers to investigate why mobile applications are
not preferred by medical providers even for communicating negative test results and what new
approaches must be taken to create mobile applications that meet the needs of medical providers.
Table 6. Bivariate Analysis of understanding why POC could be useful.
Variables N
(Percent)
OR 95% CI P-Value
I know what POC is
Yes 309 (89.83) 35.6593 14.9342–
85.1460
<.0001
No 35 (10.17)
First time hearing the term POC
Yes 308 (89.53) 2.6974 1.3164–5.5271 0.0070
No 36 (10.47)
How long have you been in the practice of medicine?
0–5 years (reference) 56 (16.28) 1 - -
6–15 years 142 (41.28) 0.339 0.074–1.541 0.6539
16 years or more 146 (42.44) 0.233 0.053–1.033 0.0448
What percentage of your patient population is on Medicaid?
< = 50% (reference) 109 (31.78) 1 - -
51%-75% 183 (53.35) 0.926 0.411–2.086 0.4992
> = 75% 51 (14.87) 0.53 0.196–1.438 0.1736
How many patients do you see per day?
0–10 patients 22 (6.40) 1 - -
11–20 patients 110 (31.98) 0.686 0.144–3.257 0.0852
21–30 patients 141 (40.99) 0.683 0.147–3.173 0.0731
31–40 patients 49 (14.24) 4.798 0.411–55.951 0.139
More than 40 patients 22 (6.40) 2.1 0.176–25.010 0.6157
How much time do you spend with a patient per visit during an annual check-up?
< = 20 minutes (reference) 134 (38.95) 1 - -
21–30 minutes 156 (45.35) 0.841 0.404–1.750 0.2089
> = 30 minutes 54 (15.70) 1.983 0.546–7.199 0.2156
How much time do you or members of your team spend discussing cancer screening
recommendations?
< = 5 minutes (reference) 86 (25.00) 1 - -
5–10 minutes 189 (54.94) 1.69 0.824–3.466 0.9603
> = 10 minutes 69 (20.06) 3.018 - -
Gender
Male 192 (55.81) 0.9884 0.4934–1.9800 0.9737
Female 152 (44.19)
Position
Advanced nurse practitioner 80 (23.26) 0.3279 0.1608–0.6687 0.0015
Primary Care Physicians 264 (76.74)
Organization type
Academic medical center (reference) 115 (33.43) 1 - -
Hospital–non-academic 142 (41.28) 0.336 0.130–0.867 0.0667
Community health center 87 (25.29) 0.424 0.148–1.215 0.4502
doi:10.1371/journal.pone.0145215.t006
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Our study results also revealed the importance of defining the scope of POC cancer screen-
ing technology in setting the appropriate expectations of end-users of the technology. System-
level barriers, such as difficulty scheduling for a screening test, multiple steps/days to obtain a
screening result, and the lack of efficient follow-up/monitoring system, could be addressed
with POC technology by providing cancer care at the point where patient care is given. By per-
forming the screening test where patient care is given, patients no longer need to wait for the
specialist to become available, or return to the hospital for the screening test, and clinicians do
not need to follow-up with patients to monitor their screening status. However, some of the
provider-level barriers recognized by our study participants, such as having to discuss compet-
ing health risks with patients and lack of support staff, fall outside of the current scope of POC
technology. Systemic changes must be made in order to resolve these provider-level barriers.
Through our study, we wanted to deliver insights and guidelines to clinicians and biomedi-
cal engineers as they continue to adopt and develop new POC cancer screening technology.
According to our survey results, medical providers believe that there is a need for a cancer
screening test with rapid data availability and ability to find cancer in its early stage. These pref-
erences of medical providers must be considered in developing a new POC technology in order
to allow the new technology to be widely adopted in current medical practice. Similar survey
studies should be performed for specific prototypes in order to gain more detailed information
for such devices to be welcomed by the medical community.
An interesting study finding was that clinicians were most interested in developing POC
technology for colorectal cancer compared to breast and prostate cancer. Among the three can-
cer types included in this survey, prostate cancer screening test has been most controversial,
which resulted in the continuing search for a better biomarker than PSA [18]. Therefore, we
hypothesized that there would be more interest in developing a new POC technology for pros-
tate cancer than for breast or colorectal cancer. However, our results show that primary care
providers consider colorectal cancer as an area of need for POC technology. One possibility for
this finding is that even though a colonoscopy is widely accepted as an effective screening tool,
there are other factors such as patients not following up after referral to obtain a colonoscopy,
their inability to afford one, or fear of pain that clinicians believe that POC technology may be
able to address for colorectal cancer [19,20].
Table 7. Multivariate Analysis of understanding why POC could be useful.
Variables N (Percent) OR 95% CI P-Value
I know what POC is
Yes 309 (89.83) 30.471 12.525–74.130 <.0001
No 35 (10.17) - - -
First time hearing the term POC
Yes 308 (89.53) 2.418 1.153–5.071 0.0195
No 36 (10.47) - - -
Position
Advanced nurse practitioner 80 (23.26) 0.322 0.147–0.705 0.0046
Primary Care Physicians 264 (76.74) - - -
How long have you been in the practice of medicine?
0–5 years (reference) 56 (16.28) 1 - -
6–15 years 142 (41.28) 0.365 0.079–1.677 0.5159
16 years or more 107 (31.10) 0.246 0.055–1.101 0.0509
doi:10.1371/journal.pone.0145215.t007
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We found that primary care providers who understood why POC technology could be use-
ful were more likely to be interested in using POC technology compared to providers who did
not. The possible explanation for this association is that providers who value POC technology
by believing it to be useful are likely to have their value of POC technology extend to interest in
its further use. A previous study completed on physician and medical technology demonstrated
“perceived usefulness” as a strong predictor of physician interest in use of medical technology
(23). Our study results reinforce this finding with understanding why POC technology could
be useful being the strongest statistical predictor of interest in POC. Potential end-users of
POC cancer screening technology must be given a thorough explanation of benefits and draw-
backs of the technology for them to make an informed decision about using such technology in
their practice.
There are several limitations to our study. The nature of the online survey form makes it dif-
ficult to estimate how many people were invited to participate in the survey and to verify the
demographic information of the participants. Additionally, this distribution method limits our
ability to estimate response rates among the participating hospitals and community centers.
Those who answered may have been more interested in POC technologies, thus contributing
to the high level of interest observed in the survey. Furthermore, we did not collect information
regarding respondent’s prior use of POC technology, a variable that may have provided an
additional explanation for interest in POC technology.
Finally, in the definition of POC technology given at the beginning of the survey, no exam-
ples of POC technology were provided to respondents. While we believe this definition to be
comprehensive, there is a risk that a respondent’s interpretation of our definition to actual
devices in practice was not what we envisioned. No questions were asked to ascertain what spe-
cific devices respondents thought fell within our definition of POC technology, therefore we
cannot be certain how they interpreted POC technology.
While there is a need to further investigate the benefits, drawbacks, and physicians’ prefer-
ences of POC cancer screening technology, as well as the existing clinical needs in cancer care,
our results suggest that there is potential for POC cancer screening technology to be widely
adopted in current medical practice. Future investigators should consider additional research
to identify the cancer type-specific factors and desired attributes of a new POC technology that
may influence medical providers’ decisions to utilize POC technology. More targeted questions
related to a specific cancer type or a specific device should be asked to clinicians in order to
provide more detailed, useful information to POC developers. Biomedical engineers could then
utilize those data to ensure that development of a new POC technology addresses the existing
clinical needs and preferences of medical providers in providing cancer care.
New medical devices and technologies are often welcomed by patients, patient’s family
members, and medical providers because of their belief that new technologies, simply because
they are new, may offer improved patient care. However, the development and introduction of
new medical technology has shown to be one of the primary reasons behind the increased cost
of health care delivery in the United States [21]. Advances in technology are only worth it
when the benefits outweigh the costs [22]. Therefore, the cost of health care delivery also needs
to be taken into account when developing a new POC technology in order for it to be widely
utilized and bring benefits to the low-income, underserved populations.
In summary, there is a great interest in POC cancer screening technology utilization among
primary care providers and growing opportunity for future investigations to take place to better
understand the existing needs and interest in using POC cancer technology. Well-developed
POC cancer screening tools will be able to provide better cancer care to patients in both devel-
oped and developing countries.
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